Day: February 24, 2025

Foresight to equip autonomous drones and unmanned aerial vehicles with NVIDIA Jetson Orin platform for enhanced real-time perception, obstacle detection, and energy efficiency across diverse applications NESS ZIONA, Israel, Feb. 24, 2025 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), a leading innovator in 3D perception systems, announces the integration of NVIDIA Jetson Orin computing platforms into its cutting-edge perception technologies. The collaboration leverages NVIDIA Jetson Orin Nano and NVIDIA Jetson AGX Orin platforms to enhance the capabilities of Foresight’s 3D perception systems across various industries, with focus on autonomous drone and unmanned aerial vehicles (UAV). The NVIDIA Jetson Orin platform provides Foresight’s vision systems with state-of-the-art...

Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already delivered Trial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA approval Two patients in the ongoing phase 2 trial have now exceeded 17 months on stenoparib treatmentBoston (February 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the new protocol for its Phase 2 clinical trial of stenoparib in ovarian cancer is set to begin and will be expected to provide critical data by end of summer...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the full year 2024, after U.S. markets close on Wednesday, March 26, 2024. Following the release, Alvotech will conduct a conference call for analysts on Thursday, March 27, 2025, at 8:00 am ET (12 noon GMT). Live audio of the conference call will be webcast and available to members of the news media, investors and the general public. Information on how to access the webcast or participate by conference call is posted on Alvotech’s earnings calendar and can be found here: https://investors.alvotech.com/events/event-details/q4-2024-earnings-full-year. The webcast will be archived and available for replay for 90 days after the event on Alvotech’s...

TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) — Allied Properties Real Estate Investment Trust (“Allied”) (TSX:AP.UN) today announced that it has received approval from the Toronto Stock Exchange (“TSX”) for a normal course issuer bid (“NCIB”) which will enable it to purchase up to 12,615,599 of its 127,955,983 issued and outstanding units (“Units”) as at February 12, 2025, representing approximately 10% of its public float of 126,155,990 Units as at that date. Allied intends to commence the NCIB on February 26, 2025. The NCIB will expire on February 25, 2026, or such earlier date as Allied completes its purchases pursuant to the NCIB. All purchases under the NCIB will be made on the open market through the facilities of the TSX and/or alternate trading systems in Canada at market prices prevailing at the time of purchase. In accordance...

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy...